CL2018001213A1 - Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16) - Google Patents

Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16)

Info

Publication number
CL2018001213A1
CL2018001213A1 CL2018001213A CL2018001213A CL2018001213A1 CL 2018001213 A1 CL2018001213 A1 CL 2018001213A1 CL 2018001213 A CL2018001213 A CL 2018001213A CL 2018001213 A CL2018001213 A CL 2018001213A CL 2018001213 A1 CL2018001213 A1 CL 2018001213A1
Authority
CL
Chile
Prior art keywords
compositions
bond
amino group
free
methods
Prior art date
Application number
CL2018001213A
Other languages
English (en)
Inventor
Premchandran H Ramiya
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of CL2018001213A1 publication Critical patent/CL2018001213A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona un método de fase sólida para realizar oligonucleótidos mediante ciclos de acoplamiento secuenciales que incluyen al menos un acoplamiento de una subunidad de dímero de dinucleótido, con un grupo de extremo 3 libre de una cadena en crecimiento. Los oligonucleótidos incluyen al menos dos subunidades de nucleósido unidas por un enlace fosforamidato N3 P5. El método puede incluir los pasos de (a) desproteger el grupo amino 3 protegido de un nucleósido de extremo unido a un soporte de fase sólida, dicha desprotección forma un grupo amino 3' libre; (b) poner en contacto el grupo amino 3' libre con un dímero de amino-dinucleótido-5'-fosforamidita 3 protegido en presencia de un catalizador nucleofilico para formar un enlace de fosforamidita N3—P5' internucleósido; y (e) oxidar (por ejemplo, sulfar) e) enlace. Las composiciones producidas por los métodos de la presente pueden incluir una cantidad reducida de uno o más productos de oligonucléotido (Nx). También se proporcionan composiciones farmacéuticas que incluyen las composiciones de oligonucleótido de la presente. 
CL2018001213A 2014-05-01 2018-05-04 Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16) CL2018001213A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US201562151909P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
CL2018001213A1 true CL2018001213A1 (es) 2018-08-03

Family

ID=54359301

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2016002749A CL2016002749A1 (es) 2014-05-01 2016-10-28 Una composición reducida en impurezas n-1 que comprende un compuesto de polinucleótido unido por enlaces inter-subunidad de fosforamidato n3-p5 o una sal farmacéuticamente aceptable del mismo y su método de síntesis en base a dímeros de amino-dinucleótido fosforamidato-5-fosforamidita-3 protegido.
CL2018001212A CL2018001212A1 (es) 2014-05-01 2018-05-04 Composiciones de oligonucleótidos y métodos para realizarlas (divisional de sol. n°2749-16)
CL2018001213A CL2018001213A1 (es) 2014-05-01 2018-05-04 Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16)
CL2022000202A CL2022000202A1 (es) 2014-05-01 2022-01-26 Composiciones de oligonucleótidos y métodos para realizarlas (divisional de la solicitud no. 201602749)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2016002749A CL2016002749A1 (es) 2014-05-01 2016-10-28 Una composición reducida en impurezas n-1 que comprende un compuesto de polinucleótido unido por enlaces inter-subunidad de fosforamidato n3-p5 o una sal farmacéuticamente aceptable del mismo y su método de síntesis en base a dímeros de amino-dinucleótido fosforamidato-5-fosforamidita-3 protegido.
CL2018001212A CL2018001212A1 (es) 2014-05-01 2018-05-04 Composiciones de oligonucleótidos y métodos para realizarlas (divisional de sol. n°2749-16)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000202A CL2022000202A1 (es) 2014-05-01 2022-01-26 Composiciones de oligonucleótidos y métodos para realizarlas (divisional de la solicitud no. 201602749)

Country Status (33)

Country Link
US (6) US9796747B2 (es)
EP (2) EP4286519A3 (es)
JP (7) JP7040892B2 (es)
KR (4) KR20240144488A (es)
CN (3) CN106459134B (es)
AP (1) AP2016009489A0 (es)
AU (3) AU2015253158B2 (es)
BR (1) BR112016025196B1 (es)
CL (4) CL2016002749A1 (es)
DK (1) DK3137479T5 (es)
EA (1) EA034882B9 (es)
ES (1) ES2963740T3 (es)
FI (1) FI3137479T3 (es)
HR (1) HRP20231505T1 (es)
HU (1) HUE064289T2 (es)
IL (2) IL248044B (es)
JO (2) JOP20200257A1 (es)
LT (1) LT3137479T (es)
MA (1) MA63525B1 (es)
MX (2) MX382233B (es)
MY (2) MY178617A (es)
PE (1) PE20170147A1 (es)
PH (1) PH12016502080A1 (es)
PL (1) PL3137479T3 (es)
PT (1) PT3137479T (es)
RS (1) RS64860B1 (es)
SG (2) SG11201608226YA (es)
SI (1) SI3137479T1 (es)
SM (1) SMT202300405T1 (es)
TW (2) TWI709406B (es)
UA (1) UA126108C2 (es)
WO (1) WO2015168310A1 (es)
ZA (2) ZA201606624B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171705T1 (hr) 2004-07-02 2017-12-15 Geron Corporation Sinteza zaštićenih 3’-amino-nukleozidnih monomera
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
CA3195922A1 (en) * 2017-07-10 2019-01-17 Geron Corporation Improved process for preparing imetelstat
EP4051252A4 (en) 2019-10-28 2023-12-06 Geron Corporation CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO -1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYL ETHER-PROPANE AND METHODS OF MANUFACTURE AND USE THEREOF
IL292328B2 (en) * 2019-10-28 2025-10-01 Geron Corp Succinylate-converted 3-(amido fatty acid)-2-hydroxy-1-(protected hydroxy)-propane salts, amorphous solids and methods for their preparation
US20240391945A1 (en) * 2020-01-08 2024-11-28 Nitto Denko Corporation Nucleic acid synthesis method using segment-type amidite
CA3234383A1 (en) 2021-10-15 2023-04-27 Codexis, Inc. Engineered terminal deoxynucleotidyl transferase variants
KR20250008345A (ko) 2023-07-07 2025-01-14 주식회사 엘지에너지솔루션 체결기구 및 체결기구를 포함하는 전지팩

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
AU7759291A (en) 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
WO1995011253A1 (en) 1993-10-18 1995-04-27 The Walter And Eliza Hall Institute Of Medical Research A method for enhancing neurone survival and agents useful for same
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
CZ274596A3 (en) 1994-03-18 1997-03-12 Lynx Therapeutics Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
RO117328B1 (ro) 1994-07-07 2002-01-30 Geron Corp Componenta rna a telomerazei de mamifere, plasmida recombinanta, de exprimare a acesteia, si metoda pentru detectarea prezentei unei stari neoplazice
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
CN1165508A (zh) 1994-11-07 1997-11-19 海布里顿公司 利用3h-1,2-苯并二硫酚-3-1,1二氧化物合成35s-标记的寡核苷酸
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) * 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
CN1317291C (zh) * 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
CA2440322C (en) * 2001-03-23 2014-09-09 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) * 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
PL1667522T3 (pl) 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
HRP20171705T1 (hr) 2004-07-02 2017-12-15 Geron Corporation Sinteza zaštićenih 3’-amino-nukleozidnih monomera
US7427675B2 (en) * 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
JP2008523786A (ja) * 2004-10-18 2008-07-10 コドン デバイシズ インコーポレイテッド 高忠実度合成ポリヌクレオチドのアセンブリ方法
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8153604B2 (en) * 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
LT2898887T (lt) 2006-10-30 2018-11-12 Geron Corporation Telomerazės inhibitoriaus ir gemcitabino derinys vėžio gydymui
US8785409B2 (en) * 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Also Published As

Publication number Publication date
JP2018131453A (ja) 2018-08-23
CN111228288B (zh) 2023-10-20
MY196927A (en) 2023-05-11
CN106459134B (zh) 2020-02-18
SMT202300405T1 (it) 2024-01-10
TWI712413B (zh) 2020-12-11
IL248044A0 (en) 2016-11-30
SG10201911086XA (en) 2020-01-30
CL2018001212A1 (es) 2018-08-03
IL268570B (en) 2021-10-31
BR112016025196B1 (pt) 2022-08-02
CN117357548A (zh) 2024-01-09
MX2016014178A (es) 2017-05-04
EP3137479B1 (en) 2023-08-30
JP7040892B2 (ja) 2022-03-23
AU2015253158A1 (en) 2016-10-20
AU2015253158B2 (en) 2019-12-12
US11739114B2 (en) 2023-08-29
ZA201606624B (en) 2020-12-23
KR102707216B1 (ko) 2024-09-19
HRP20231505T1 (hr) 2024-03-01
JO3767B1 (ar) 2021-01-31
DK3137479T5 (da) 2024-10-14
EP4286519A3 (en) 2024-02-28
MA63525A1 (fr) 2024-09-30
TW201622732A (zh) 2016-07-01
NZ724764A (en) 2021-02-26
KR20160147768A (ko) 2016-12-23
PH12016502080A1 (en) 2017-01-09
TWI709406B (zh) 2020-11-11
JP2026016798A (ja) 2026-02-03
US20180016293A1 (en) 2018-01-18
PE20170147A1 (es) 2017-04-12
JP2023073510A (ja) 2023-05-25
ES2963740T3 (es) 2024-04-01
IL268570A (en) 2019-09-26
IL248044B (en) 2019-08-29
PT3137479T (pt) 2023-11-30
SG11201608226YA (en) 2016-10-28
CL2016002749A1 (es) 2017-04-28
DK3137479T3 (da) 2023-11-20
KR20230088509A (ko) 2023-06-19
AP2016009489A0 (en) 2016-10-31
TW202017574A (zh) 2020-05-16
MY178617A (en) 2020-10-19
US9796747B2 (en) 2017-10-24
US20240150391A1 (en) 2024-05-09
CL2022000202A1 (es) 2023-02-10
NZ763996A (en) 2021-03-26
EP3137479A4 (en) 2018-02-07
EA034882B9 (ru) 2020-07-13
JP7308309B2 (ja) 2023-07-13
BR112016025196A2 (pt) 2017-12-12
SI3137479T1 (sl) 2023-11-30
PL3137479T3 (pl) 2024-02-26
AU2020201707A1 (en) 2020-03-26
JP2021182946A (ja) 2021-12-02
JOP20200257A1 (ar) 2017-06-16
CA2943888A1 (en) 2015-11-05
MA63525B1 (fr) 2025-02-28
EP3137479A1 (en) 2017-03-08
US10392418B2 (en) 2019-08-27
JP7736489B2 (ja) 2025-09-09
KR102316282B1 (ko) 2021-10-25
US20220306676A1 (en) 2022-09-29
US20250011359A1 (en) 2025-01-09
LT3137479T (lt) 2023-10-10
US20180016294A1 (en) 2018-01-18
UA126108C2 (uk) 2022-08-17
ZA202005857B (en) 2024-01-31
EA034882B1 (ru) 2020-04-01
US20150337314A1 (en) 2015-11-26
FI3137479T3 (fi) 2023-11-28
MX2021004932A (es) 2021-08-16
JP2017514479A (ja) 2017-06-08
JP2022044679A (ja) 2022-03-17
RS64860B1 (sr) 2023-12-29
EP4286519A2 (en) 2023-12-06
CN106459134A (zh) 2017-02-22
KR20210130822A (ko) 2021-11-01
AU2020201707B2 (en) 2022-02-17
MX382233B (es) 2025-03-13
JP2020050670A (ja) 2020-04-02
EA201691786A1 (ru) 2017-04-28
HUE064289T2 (hu) 2024-02-28
WO2015168310A1 (en) 2015-11-05
US11299511B2 (en) 2022-04-12
KR20240144488A (ko) 2024-10-02
AU2022203273A1 (en) 2022-06-02
CN111228288A (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
CL2018001213A1 (es) Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16)
BR112014009066B8 (pt) molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica
ECSP18010463A (es) Composiciones de oligonucleótidos y métodos de los mismos
ECSP14010277A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
MX2018012038A (es) Agentes de iarn modificados.
CL2013002990A1 (es) Compuestos derivados de imidazo[5,1-a]isoindol o sus sales, inhibidores de indolamina 2,3-dioxigenasa (ido); composicion farmaceutica, utiles para tratar la inmunosupresion asociada con una enfermedad infecciosa o cancer.
MX2016016905A (es) Ensamblaje de adn mediado por nucleasa.
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
CL2013000445A1 (es) Quelato de oligonucleotidos que comprende dos o mas oligonucleotidos enlazados por un cation multivalente donde al menos un oligonucleotido de dicho complejo tiene al menos un enlace fosforotioato; composicion farmaceutica que lo comprende; y sus usos.
ECSP13012438A (es) Proceso para preparar compuestos antivirales
UY33270A (es) Sales cristalinas de un potente inhibidor del hcv
UY29408A1 (es) Productos de microcápsula de liberación rápida.
PE20141155A1 (es) Analogos del acido epoxi-eicosatrienoico y metodos para hacer y de uso del mismo
AR100946A1 (es) Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn
CR20110524A (es) Proceso para preparar compuestos antivirales
AR100235A1 (es) Composiciones de oligonucleótidos y métodos para realizarlas
AR086925A1 (es) Metodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih)
CL2013003466A1 (es) Construcción de arn que comprende una secuencia de segmento sentido y una antisentido del gen p0 del genoma del virus del amarilleo moderado de la remolacha (bmyv), metodo para inducir tolerancia al virus bmyv.
EA202090282A1 (ru) Композиции олигонуклеотидов и способы их получения
TH166778A (th) องค์ประกอบโอลิโกนิวคลีโอไทด์และวิธีการในการทำองค์ประกอบนี้
AR108914A1 (es) Oligómeros para el salteo de exones en la distrofia muscular
AR105066A1 (es) Enzimas y sistemas crispr